Ark Invest CEO Cathie Wood stated that gold is headed lower while Bitcoin is set to keep gaining, despite Bitcoin's recent price dip below $75,000. She highlighted that since 2019, Bitcoin and gold have shown almost no correlation, meaning Bitcoin moves independently of gold. Wood believes Bitcoin will outperform gold over time as it "marches to its own beat." However, recent market movements show gold rising and Bitcoin struggling ahead of the upcoming U.S. CPI report, which could influence Federal Reserve interest rate decisions and impact both assets.
Cathie Wood's views on gold and Bitcoin provide context for readers, with Pluang market data as of Nov 10, 2026 17:41 WIB. Among 50 major cryptocurrencies on Pluang, 33 rose and 16 fell today. Notable movers include SXP (Solar) down 46.27% at Rp37, ONE (Harmony) up 32.50% at Rp37 with a typical hold time of 153 days and a 58% sell order activity, and BAL (Balancer) up 11.14% at Rp16.297.
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
ESET Research uncovered a sophisticated cyberespionage tool named Cereal, used by the Russia-aligned Turla group to spy on emails within Microsoft Exchange servers of governmental organizations in Kazakhstan and Romania. The tool stealthily collects ...
The global paracetamol market is projected to grow from $12.05 billion in 2026 to $15.39 billion by 2032, with a CAGR of 4.12%. Growth is driven by increasing demand for pain and fever management, expanded access to over-the-counter medicines, and in...
Registration is now open for Brand Licensing Expo 2027, scheduled for May 25-27 at Mandalay Bay, Las Vegas. The event, rebranded from Licensing Expo, features over 265 confirmed exhibitors including major brands like Amazon MGM Studios, Coca-Cola, an...
Trogenix, a clinical-stage precision oncology company, has appointed John Young as Chair and Josh Murray as Non-Executive Director to support its global strategy, commercial growth, and US expansion. John Young brings over 35 years of pharmaceutical ...
